Publicacións nas que colabora con MI KWON KIM (60)

2024

  1. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy

    Blood transfusion = Trasfusione del sangue, Vol. 22, Núm. 3, pp. 239-245

  2. Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients

    Transplantation and Cellular Therapy, Vol. 30, Núm. 3, pp. 306.e1-306.e12

  3. Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study

    The Lancet HIV, Vol. 11, Núm. 6, pp. e389-e405

2023

  1. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

    Haematologica, Vol. 108, Núm. 1, pp. 110-121

  2. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

  3. Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma

    Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 472.e1-472.e4

  4. Novel Candidate loci and Pathogenic Germline Variants Involved in Familial Hematological Malignancies Revealed by Whole-Exome Sequencing

    Cancers, Vol. 15, Núm. 3

  5. Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide

    Annals of Hematology, Vol. 102, Núm. 6, pp. 1561-1567

  6. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

    Bone Marrow Transplantation, Vol. 58, Núm. 8, pp. 907-915

2022

  1. Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation

    Frontiers in immunology, Vol. 13, pp. 1002959

  2. Autopsy Study Defines Composition and Dynamics of the HIV-1 Reservoir after Allogeneic Hematopoietic Stem Cell Transplantation with CCR5Δ32/Δ32 Donor Cells

    Viruses, Vol. 14, Núm. 9

  3. FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 16

  4. Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC

    Transplantation and Cellular Therapy, Vol. 28, Núm. 4, pp. 204.e1-204.e10

  5. Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms

    Annals of Hematology, Vol. 101, Núm. 7, pp. 1567-1576

2021

  1. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 12

  2. Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 12

  3. Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant

    Frontiers in Immunology, Vol. 12

  4. Next generation cytogenetics in myeloid hematological neoplasms: Detection of cnvs and translocations

    Cancers, Vol. 13, Núm. 12

  5. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation

    Annals of Hematology, Vol. 100, Núm. 2, pp. 541-553

  6. Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease

    Journal of Oncology Pharmacy Practice, Vol. 27, Núm. 3, pp. 751-755